6,8-diazaspiro[4.5]dec-7-en-7-amine hydrobromide | 753023-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 6,8-diazaspiro[4.5]dec-7-en-7-amine hydrobromide
• 英文别名: 6,8-Diazaspiro[4.5]dec-7-en-7amine hydrobromide；6,8-diazaspiro[4.5]dec-7-en-7-amine;hydrobromide
• CAS: 753023-67-5
• 化学式: BrH*C₈H₁₅N₃
• 分子量: 234.139
• InChiKey: NTLNGNJJHRLYQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.19
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  50.4
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,8-diazaspiro[4.5]dec-7-en-7-amine hydrobromide 、 1'-[(2S)-2-Hydroxy-2-phenylethyl]-8'-pyridin-4-yl-3',4'-dihydrospiro[cyclopentane-1,2'-pyrimido[1,2-a]pyrimidin]-6'(1'H)-one 以(1:1) (hydrochloride) The product was obtained by analogy with the method的产率得到1'-(2-Oxo-2-phenylethyl)-8'-pyridin-4-yl-3',4'-dihydrospiro[cyclopropane-1,2'-pyrimido[1,2-a]pyrimidin]-6'(1'H)-one
  参考文献：
  名称：

  Substituted 8′-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives

  摘要：

  本发明涉及一种由式（I）表示的二氢螺-[环烷基]-嘧啶酮衍生物或其盐：其中，X、Y、R1、R2、R3、m、n、p和q如所述。本发明还涉及一种药物，该药物包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，例如阿尔茨海默病。

  公开号：

  US07294632B2

文献信息

• Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives
  申请人：George Pascal

  公开号：US20060025431A1

  公开（公告）日：2006-02-02

  The invention relates to a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  该发明涉及一种由式（I）表示的二氢螺-[环烷基]-嘧啶酮衍生物或其盐：其中X、Y、R1、R2、R3、m、n、p和q如本文所述。该发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE DERIVATIVES
  申请人：GEORGE Pascal

  公开号：US20080081819A1

  公开（公告）日：2008-04-03

  The invention relates to therapeutic uses of a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. Specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种二氢螺[环烷基]嘧啶酮衍生物或其盐的治疗用途，其化学式如下：其中X、Y、R1、R2、R3、m、n、p和q如本文所述。具体而言，本发明涉及一种药物，包括上述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• Substituted 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one derivatives and their use against neurodegenerative diseases
  申请人：SANOFI-SYNTHELABO

  公开号：EP1454909A1

  公开（公告）日：2004-09-08

  The invention relates to a dihydrospiro-[cycloalkyl]-pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a carbonyl group, a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted; R2 represents a benzene ring or a naphthalene ring; the rings being optionally substituted; R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; m represents 1 to 4 n represent 0 to 3 p represents 0 to 2 q represents 0 to 2, p+ q being inferior to 4. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及式 (I) 所代表的二氢螺-[环烷基]-嘧啶酮衍生物或其盐： 其中 X 代表两个氢原子、一个硫原子、一个氧原子或一个 C1-2 烷基和一个氢原子； Y 代表键、羰基、任选取代的亚甲基； R1 代表 2、3 或 4-吡啶环或 2、4 或 5-嘧啶环，环可任选被取代； R2 代表苯环或萘环；这些环可任选被取代； R3 代表氢原子、C1-6 烷基或卤素原子； m 代表 1 至 4 n 代表 0 至 3 p 代表 0 至 2 q 代表 0 至 2，p+ q 不如 4。 本发明还涉及一种包含上述衍生物或其盐作为活性成分的药物，该药物用于预防和/或治疗由 GSK3β 活性异常引起的神经退行性疾病，如阿尔茨海默病。
• SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
  申请人：Sanofi-Aventis

  公开号：EP1603915B1

  公开（公告）日：2010-05-26
• US7294632B2
  申请人：——

  公开号：US7294632B2

  公开（公告）日：2007-11-13